Phys · infectious
Vaccine-Preventable Diseases and Adult Immunisation
Also known as adult immunisation · vaccination · immunisation schedule · vaccine-preventable disease · Shingrix · recombinant zoster vaccine · pneumococcal vaccine · HPV vaccine · travel medicine · vaccine hesitancy · live vaccine contraindication · cocooning · dTpa pregnancy · asplenic vaccination
Consultant-physician-depth guide to adult immunisation in the physician context — where comorbidity, immunosuppression, pregnancy, asplenia, and travel modify the standard schedule and turn each vaccine decision into a clinical-reasoning task. Covers the Australian NIP adult schedule (annual enhanced influenza above 65, pneumococcal PCV then PPSV23 or PCV20, recombinant zoster Shingrix above 50, dTpa every pregnancy 28 to 32 weeks, HPV catch-up to 25), the live-versus-inactivated principle that governs vaccination in immunocompromise, the pre-immunosuppression window (before rituximab, anti-TNF, transplant, chemotherapy), the asplenic vaccination-plus-prophylaxis bundle, travel medicine (yellow fever, Japanese encephalitis, typhoid, rabies), vaccine adverse events (anaphylaxis, Guillain-Barre after influenza, VAPP after oral polio, intussusception after rotavirus), and the communication strategies for vaccine hesitancy — structured for FRACP DWE and DCE preparation.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Never give a live vaccine (MMR, varicella, yellow fever, BCG, oral polio, oral typhoid Ty21a, live attenuated influenza) to a severely immunosuppressed patient — the vaccine strain can cause disseminated disease; always check the degree of immunosuppression before any live vaccine
- Vaccinate BEFORE immunosuppression begins — at least 2 weeks before for inactivated vaccines and 4 weeks before for live vaccines, because vaccine responses depend on a functional immune system and B-cell-depleting therapy like rituximab renders vaccines ineffective for 6 to 12 months
- A pregnant woman must receive dTpa in EVERY pregnancy at 28 to 32 weeks, not just the first — pertussis antibody wanes between pregnancies and transplacental transfer must be maximised for each neonate
- The asplenic patient needs the full bundle — pneumococcal, meningococcal ACWY and B, Hib, and influenza, plus lifelong penicillin prophylaxis and a standby-antibiotic plan — because OPSI mortality is 50 to 70 per cent despite treatment
- Shingrix is a 2-dose inactivated vaccine, not a single dose and not live — it supersedes Zostavax and is safe in immunosuppression; a patient who received only one dose is not adequately protected
- Give the conjugate vaccine (PCV) before the polysaccharide (PPSV23) — if PPSV23 is given first, it blunts the response to subsequent PCV; the correct sequence is PCV first, then PPSV23 at least 8 weeks later, or PCV20 alone
- Yellow fever vaccine is live, only available at designated centres, and contraindicated in severe immunosuppression, thymus disorder, infants under 6 months, and pregnancy — the immunocompromised traveller needs a waiver or mosquito avoidance
Vaccine-Preventable Diseases and Adult Immunisation
[1]The one-minute consultant answer
Adult immunisation in the physician context is not the protocol-driven GP encounter — it is a clinical-reasoning task applied to the patient whose comorbidity, immunosuppression, pregnancy, asplenia, or travel plans modify the standard schedule in ways that the schedule alone cannot resolve. The physician is the doctor who sees the patient before rituximab, before anti-TNF, before transplant, before splenectomy, before international travel, and in pregnancy — the moments where the question is not "what vaccines are due?" but "what can I safely give, in what order, and by when, before the window for a useful vaccine response closes?" [1]
The central principle is: vaccinate before immunosuppression begins, because the vaccine response depends on a functional immune system [1]. Give inactivated vaccines at least 2 weeks before immunosuppression (ideally 4) and live vaccines at least 4 weeks before — because B-cell-depleting therapy like rituximab renders vaccines ineffective for 6 to 12 months, and the patient on chemotherapy or post-transplant immunosuppression cannot mount the antibody response that the vaccine requires. [1]
The second principle is the live-versus-inactivated distinction, which governs every immunisation decision in immunocompromise. Live vaccines — MMR, varicella, yellow fever, BCG, oral polio (OPV), oral typhoid (Ty21a), live attenuated influenza (intranasal), and rotavirus — replicate in the host and can cause disseminated disease in severe immunosuppression. They are contraindicated in the severely immunosuppressed (high-dose corticosteroids above 20 mg prednisolone for more than 2 weeks, chemotherapy, transplant immunosuppression, anti-CD20 therapy, HIV with CD4 below 200), and the safe inactivated alternative must be used instead. The one exception with nuance is HIV: MMR and varicella are safe if the CD4 is above 200 and the patient is clinically stable, but yellow fever is still avoided [1].
The third principle is the sequential pneumococcal schedule: give the conjugate vaccine (PCV13, PCV15, or PCV20) first because it primes T-cell-dependent immunological memory, then the polysaccharide (PPSV23) at least 8 weeks later to broaden serotype coverage — or simply give a single conjugate dose (PCV20 or PCV21) per current ACIP guidance. The CAPiTA trial demonstrated that PCV13 prevents vaccine-type community-acquired pneumonia (45.6 per cent efficacy) and invasive pneumococcal disease (75 per cent efficacy) in adults aged 65 and older [2].
References8ShowHide
- [1]Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host Clin Infect Dis, 2014.PMID 24421306
- [2]Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults N Engl J Med, 2015.PMID 25785969
- [3]Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older N Engl J Med, 2016.PMID 27626517
- [4]Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study Lancet, 2014.PMID 25037990
- [5]Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women N Engl J Med, 2015.PMID 25693011
- [6]Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination JAMA, 2004.PMID 15562126
- [7]CDC Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep, 2012.PMID 23051612
- [8]Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults N Engl J Med, 2015.PMID 25916341